A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib
机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China[2]Peking Univ, Hlth Sci Ctr, Beijing, Peoples R China[3]Liaoning Canc Hosp & Inst, Shenyang, Liaoning, Peoples R China[4]Henan Prov Peoples Hosp, Zhengzhou, Peoples R China[5]Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou, Peoples R China[6]Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Fuzhou, Peoples R China[7]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China[8]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院[9]Harbin Med Univ, Affiliated Canc Hosp, Harbin, Peoples R China[10]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China[11]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sch Med,Canc Ctr, Chengdu, Sichuan, Peoples R China四川省肿瘤医院[12]Peking Union Med Coll Hosp, Beijing, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Peng Peng,Liu Tianmou,Wang Danbo,et al.A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Peng, Peng,Liu, Tianmou,Wang, Danbo,Wang, Yue,Cheng, Ninghai...&Xiang, Yang.(2024).A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Peng, Peng,et al."A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学